Early effects of transplatin on oncogene activation in vivo

Árpád Németh, E. Nádasi, A. Beró, L. Olasz, Á Ember, A. Kvarda, L. Bujdosó, I. Arany, A. Csejtei, Zs Faluhelyi, I. Ember

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of the study was to investigate the early effect of Transplatin (the stereo-homer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Ha-ras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the "short-term" in vivo test system.

Original languageEnglish
Pages (from-to)3997-4001
Number of pages5
JournalAnticancer Research
Volume24
Issue number6
Publication statusPublished - Nov 2004

Fingerprint

Oncogenes
Cisplatin
Inbred CBA Mouse
ras Genes
p53 Genes
Body Weight
RNA
transplatin

Keywords

  • Head and neck cancer
  • Oncogene expression
  • Platinum isomers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Németh, Á., Nádasi, E., Beró, A., Olasz, L., Ember, Á., Kvarda, A., ... Ember, I. (2004). Early effects of transplatin on oncogene activation in vivo. Anticancer Research, 24(6), 3997-4001.

Early effects of transplatin on oncogene activation in vivo. / Németh, Árpád; Nádasi, E.; Beró, A.; Olasz, L.; Ember, Á; Kvarda, A.; Bujdosó, L.; Arany, I.; Csejtei, A.; Faluhelyi, Zs; Ember, I.

In: Anticancer Research, Vol. 24, No. 6, 11.2004, p. 3997-4001.

Research output: Contribution to journalArticle

Németh, Á, Nádasi, E, Beró, A, Olasz, L, Ember, Á, Kvarda, A, Bujdosó, L, Arany, I, Csejtei, A, Faluhelyi, Z & Ember, I 2004, 'Early effects of transplatin on oncogene activation in vivo', Anticancer Research, vol. 24, no. 6, pp. 3997-4001.
Németh Á, Nádasi E, Beró A, Olasz L, Ember Á, Kvarda A et al. Early effects of transplatin on oncogene activation in vivo. Anticancer Research. 2004 Nov;24(6):3997-4001.
Németh, Árpád ; Nádasi, E. ; Beró, A. ; Olasz, L. ; Ember, Á ; Kvarda, A. ; Bujdosó, L. ; Arany, I. ; Csejtei, A. ; Faluhelyi, Zs ; Ember, I. / Early effects of transplatin on oncogene activation in vivo. In: Anticancer Research. 2004 ; Vol. 24, No. 6. pp. 3997-4001.
@article{6faf09c311da4678a5eff6dc65449a35,
title = "Early effects of transplatin on oncogene activation in vivo",
abstract = "The aim of the study was to investigate the early effect of Transplatin (the stereo-homer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Ha-ras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the {"}short-term{"} in vivo test system.",
keywords = "Head and neck cancer, Oncogene expression, Platinum isomers",
author = "{\'A}rp{\'a}d N{\'e}meth and E. N{\'a}dasi and A. Ber{\'o} and L. Olasz and {\'A} Ember and A. Kvarda and L. Bujdos{\'o} and I. Arany and A. Csejtei and Zs Faluhelyi and I. Ember",
year = "2004",
month = "11",
language = "English",
volume = "24",
pages = "3997--4001",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Early effects of transplatin on oncogene activation in vivo

AU - Németh, Árpád

AU - Nádasi, E.

AU - Beró, A.

AU - Olasz, L.

AU - Ember, Á

AU - Kvarda, A.

AU - Bujdosó, L.

AU - Arany, I.

AU - Csejtei, A.

AU - Faluhelyi, Zs

AU - Ember, I.

PY - 2004/11

Y1 - 2004/11

N2 - The aim of the study was to investigate the early effect of Transplatin (the stereo-homer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Ha-ras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the "short-term" in vivo test system.

AB - The aim of the study was to investigate the early effect of Transplatin (the stereo-homer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Ha-ras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the "short-term" in vivo test system.

KW - Head and neck cancer

KW - Oncogene expression

KW - Platinum isomers

UR - http://www.scopus.com/inward/record.url?scp=20144387473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387473&partnerID=8YFLogxK

M3 - Article

C2 - 15736445

AN - SCOPUS:20144387473

VL - 24

SP - 3997

EP - 4001

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -